99m Technetium-HMPAO-labeled platelet scan in practice
Preparation, quality control, and biodistribution studies
DOI:
https://doi.org/10.1590/s2175-97902022e18860Keywords:
Platelet; 99mTc-HMPAO; Biodistribution; Labeling efficiency; Platelet extractionAbstract
There is no biodistribution or imaging data on 99mtechnetium (Tc)-hexamethyl propylamine oxime (HMPAO)-labeled platelets in the literature. The current study aimed to present updated information about the clinical procedures for preparation and use of labeled platelets. Following two-step centrifugation at 1500 and 2500 rpm, the platelets were extracted from whole blood into platelet-rich plasma (PRP) above the buffy coat and then from PRP into a platelet pellet at the bottom of the tube. The 99mTc-HMPAO-labeled platelets were inspected for purity, viability, release of 99mTc from platelets, and sterility. Also, microscopic examination and thin layer chromatography (TLC) were performed. Biodistribution was assessed following necropsy in BALB/c mice and through imaging of New Zealand rabbits. The separation ratio was estimated at 98%, and radiochemical purity was measured to be 80%. The labeling efficiency was above 30% in more than half of the assays (range: 17-43%). The release of 99mTc from platelets was 9% per hour at 37ºC. After 24 hours, stability was estimated at 54% in the human serum. The target organs of mice included the spleen and liver. In rabbits, the imaging results indicated liver as the target organ. Thyroid uptake was negligible up to 90 minutes. Based on the findings, extraction of platelets and labeling them with 99mTc-HMPAO is a feasible and safe approach in routine practice.
Downloads
References
Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000;18(20):3495-502.
Banerjee S, Samuel G, Kothari K, Sarma HD, Pillai MR. On the synthesis, isolation, and radiochemical studies for the preparation of in-house kits for 99mTc-meso-and d, l-HMPAO: A few additional observations. Nuclear Med Biol. 1999;26(3):327-38.
Becker W, Börner W, Borst U. 99Tcm hexamethylpropyleneamineoxime (HMPAO) as a platelet label: evaluation of labelling parameters and first in vivo results. Nuclear Med Commun. 1988;9(10):831-42.
Becker W, Borner W, Borst U, Kromer EP, Gruner KR. Tc- 99m-HMPAO: a new platelet labelling compound. Eur J Nucl Med. 1987;13:267-8.
Becker W, Borst U, Krahe T, Börner W. Tc-99m-HMPAO labelled human platelets: in vitro and in vivo results. Eur J Nucl Med. 1989;15(6):296-301.
Danberry K, Burton B, McCleod C. Effects on Red Blood Cell Labeling Protocols due to USP 797 revisions. J Nucl Med. 2015;56(supplement 3): 2738-2738.
Erik F, de Vries J, Roca M, Jamar F, Israel O, Signore A. Guidelines for the labelling of leucocytes with 99mTc- HMPAO. Eur J Nucl Med Mol Imaging. 2010;37(4):842.
Decristoforo C, Siller R, Chen F, Riccabona G. Radiochemical purity of routinely prepared 99Tcm radiopharmaceuticals: a retrospective study. Nucl Med Commun. 2000;21(4):349-54.
Goodwin DA, Lang EV, Atwood JE, Dalman RL, Ransone CM, Diamanti CI, McTigue M. Viability and biodistribution of 68Ga MPO-labelled human platelets. Nucl Med Commun . 1993;14(11):1023-9.
Haugland R. Assays for cell viability, proliferation and function. Handbook of Fluorescent Probes and Research Chemicals. 1996;365-398
Knight LC, Romano JE, Bright LT, Agelan A, Kantor S, Maurer AH. Platelet binding and biodistribution of [99mTc] rBitistatin in animal species and humans. Nucl Med Biol. 2007;34(7):855-63.
Martín-Comín J, Thakur ML, Piera C, Roca M, Lomeña F, editors. Radiolabeled blood elements: Recent advances in techniques and applications. Springer Science & Business Media; 2012 Dec 6.
Mirahmadi N, Babaei MH, Vali AM, Daha FJ, Kobarfard F, Dadashzadeh S. 99mTc-HMPAO-labeled liposomes: an investigation into the effects of some formulation factors on labeling efficiency and in vitro stability. Nucl Med Biol. 2008;35(3):387-92.
Mozaffari S, Erfani M, Beiki D, Daha FJ, Kobarfard F, Balalaie S, et al. Synthesis and preliminary evaluation of a new 99mTc labeled substance P analogue as a potential tumor imaging agent. Iranian J Pharm Res. 2015;14(1):97.
Pillai, M. Technetium-99m radiopharmaceuticals: manufacture of kits. Vienna: International Atomic Energy Agency. 2008
Rodrigues M, Sinzinger H, Thakur M, Becker W, Dewanjee M, Ezekowitz M, et al. Labelling of platelets with indium-111 oxine and technetium-99m hexamethylpropylene amine oxime: suggested methods. Eur J Nucl Med. 1999;26(12):1614-6.
Shamshirian D, Erfani M, Beiki D, Hajiramazanali M, Fallahi B. A 99mTc-tricine-HYNIC-labeled peptide targeting the melanocortin-1 receptor for melanoma imaging. Iranian journal of pharmaceutical research: IJPR. 2016;15(3):349.
Tafakhori A, Parvizi M, Farzanefar S, Ahmadzadehfar H, Khalaj A, Naseri M, Abbasi M. Clinical use of 99m Tc- HMPAO-labeled platelets in cerebral sinus thrombosis imaging. Acta Neurol Belg. 2019;119(4):549-53.
USP XIX, U. P.United States Pharmacopeial Convention. Rockville. 1975. Md 463.
von Bruchhausen F, Walter U, editors. Platelets and their factors. Springer Science & Business Media; 2012 Dec 6.
Vorne M, Honkanen T, Karppinen K, Röning M, Sakki S. Radiolabelling of human platelets with 99mTc-HMPAO. Eur J Haematol. 1989;42(5):487-91.
Vorne MS, Honkanen TT, Lantto TJ, Laitinen RO, Karppinen KJ, Jauhola SV. Thrombus imaging with 99mTc-HMPAO- labeled platelets and 111In-labeled monoclonal antifibrin antibodies. Acta Radiol. 1993;34(1):59-63.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
